BioNTech SE - ADR BNTX shares are trading higher by 6.31% at $142.50 after the company announced its Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response against the Omicron variant.
Pfizer Inc. PFE and BioNTech said data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies' current COVID-19 vaccine. The robust immune response was seen across two investigational dose levels, 30 µg and 60 µg.
See Also: Why Axsome Therapeutics Stock Is Soaring Today
BioNTech is a Germany-based biotechnology company.
According to data from Benzinga Pro, BioNTech has a 52-week high of $464.00 and a 52-week low of $117.08.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
